Drugs / GSK2981278
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02548052 | Oct 2015 → Feb 2016 | psoriasis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03004846 | Feb → May 2017 | psoriasis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2981278 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02548052 ↗ |
| Known as | Ror gama modulator 1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4225088 ↗ |
| Action | Inhibit | “GSK2981278 is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (ROR gamma)” NCT02548052 ↗ |
| Modality | Small molecule | — CHEMBL4225088 ↗ |
| Route | Topical | “Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.” NCT02548052 ↗ |